If anaplastic lymphoma kinase (ALK) gene rearrangement in lungcancer is identified, ALK-tyrosine kinase inhibitors (ALK-TKIs) can be an effec-tive treatment. However, the details of drug-induced lung injury (DILI) causedby ALK-TKI, which can be a serious side effect of ALK-TKIs, remains unclear.This study aimed to investigate the clinical features and the onset risk factors ofDILI by ALK-TKIs in clinical practice.Methods:The clinical features of 56 consecutive patients who receivedcrizotinib, alectinib, and/or ceritinib at our hospital from 2012 to 2018 were ret-rospectively examined. Among these, patients diagnosed with DILI due to ALK-TKIs were evaluated in terms of clinical features and parameters. Each clinicalparameter before the administration of ALK-TKIs was compared between theDILI onset group and the non-onset group.Results:A total of seven cases were diagnosed with DILI due to ALK-TKIs; noDILI-related deaths were observed. Chest computed tomography (CT) scanfind-ings identified six patients with the organizing pneumonia (OP) pat..... READ ARTICLE
Thoracic Cancer DOI:10.1111/1759-7714.13416
Authors: Ken Koshikawa, Jiro Terada, Mitsuhiro Abe, Shunichiro Iwasawa, Masashi Sakayori, Keiichiro Yoshioka, Yasutaka Hirasawa, Hajime Kasai, Yohei Kawasaki, Kenji Tsushima, Koichiro Tatsumi
